ArticleCell biology and toxicology2026
The PRKN/METTL3/CLDN2 axis promotes colorectal cancer development through epigenetic mechanisms.
Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDysregulation of N6-methyladenosine (m6A) RNA methylation plays a crucial role in colorectal cancer (CRC) development. Despite the established oncogenic role of methyltransferase-like 3 (METTL3) in CRC, the mechanisms behind its tumor-promoting functions are not fully understood.
methodsFunctional impacts were assessed by measuring cell viability, invasion, colony formation, migration, apoptosis, and M2 macrophage polarization in vitro, as well as in vivo tumorigenicity. The interaction between METTL3 and claudin 2 (CLDN2) was validated via RNA immunoprecipitation and luciferase assays. The PRKN/METTL3 interaction was analyzed using immunoprecipitation (IP) and Co-IP experiments. The stability of mRNA and protein levels was examined by treating cells with actinomycin D or cycloheximide.
resultsMETTL3 and CLDN2 levels were upregulated in CRC samples and cells. Depletion of METTL3 or CLDN2 suppressed CRC cell proliferation, invasion, and migration, and inhibited M2 polarization of THP-1-derived macrophages. Mechanistically, METTL3 promoted m6A methylation and stability of CLDN2 mRNA in an insulin-like growth factor 2 binding protein 2 (IGF2BP2)-dependent manner. METTL3 silencing diminished CRC cell malignant phenotypes and M2 macrophage polarization via CLDN2 reduction. Moreover, PRKN enhanced METTL3 protein degradation through K63-linked polyubiquitination. The PRKN/METTL3 axis regulated malignant phenotypes of CRC cells. Additionally, METTL3 depletion repressed tumor growth and lung metastasis of xenografts in vivo via CLDN2.
conclusionOur work uncovers a previously unrecognized PRKN-METTL3-CLDN2 signaling network that orchestrates colorectal tumorigenesis, providing a compelling rationale for developing METTL3-targeted therapies against CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.